PT  - JOURNAL ARTICLE
AU  - Hao, Shuang
AU  - Heintz, Emelie
AU  - Östensson, Ellinor
AU  - Discacciati, Andrea
AU  - Jäderling, Fredrik
AU  - Grönberg, Henrik
AU  - Eklund, Martin
AU  - Nordström, Tobias
AU  - Clements, Mark
TI  - Cost-effectiveness of Stockholm3 test and magnetic resonance imaging in prostate cancer screening: a microsimulation study
AID  - 10.1101/2021.03.31.21254617
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.31.21254617
4099  - http://medrxiv.org/content/early/2021/04/06/2021.03.31.21254617.short
4100  - http://medrxiv.org/content/early/2021/04/06/2021.03.31.21254617.full
AB  - Objective Assess the cost-effectiveness of no screening and quadrennial magnetic resonance imaging (MRI)-based screening for prostate cancer using either Stockholm3 or prostate-specific antigen (PSA) test as a reflex test.Methods Test characteristics were estimated from the STHLM3-MR study (NCT03377881). A cost-utility analysis was conducted from a lifetime societal perspective using a microsimulation model for men aged 55-69 in Sweden for no screening and three quadrennial screening strategies, including: PSA≥3ng/mL; and Stockholm3 with reflex test thresholds of PSA≥1.5 and 2ng/mL. Men with a positive test had an MRI, and those MRI positive had combined targeted and systematic biopsies. Predictions included the number of tests, cancer incidence and mortality, costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Uncertainties in key parameters were assessed using sensitivity analyses.Results Compared with no screening, the screening strategies were predicted to reduce prostate cancer deaths by 7-9% across a lifetime and were considered to be moderate costs per QALY gained in Sweden. Using Stockholm3 with a reflex threshold of PSA≥2ng/mL resulted in a 60% reduction in MRI compared with screening using PSA. This Stockholm3 strategy was cost-effective with a probability of 70% at a cost-effectiveness threshold of €47,218 (500,000 SEK).Conclusions All screening strategies were considered to be moderate costs per QALY gained compared with no screening. Screening with Stockholm3 test at a reflex threshold of PSA≥2ng/mL and MRI was predicted to be cost-effective in Sweden. Use of the Stockholm3 test may reduce screening-related harms and costs while maintaining the health benefits from early detection.Competing Interest StatementHenrik Gronberg has five prostate cancer diagnostic related patents pending. Martin Eklund is named on four of these five patent applications. Karolinska Institutet collaborates with A3P Biomedical in developing the technology for the Stockholm3 test. Henrik Gronberg, Martin Eklund and Tobias Nordstrom own shares in A3P Biomedical. All other authors declare no competing interest.Clinical TrialNCT03377881Clinical Protocols https://www.clinicaltrials.gov/ct2/show/NCT03377881 Funding StatementFunding for this study is provided by the Swedish Research Council (through the Swedish eScience Research Centre, the Cancer Risk Prediction Center and project 2018-02526), Prostatacancerforbundet, Karolinska Institutet (KID) and Cancerfonden (project CAN 2018/539).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of the data from the Stockholm PSA and Biopsy Register was approved by the Ethical Review Board, Stockholm (dnr 2012/438-31/3, dnr 2016/620-32). The STHLM3-MR Study was approved by the Ethical Review Board, Stockholm (dnr 2017/1280-31) and the registration number was NCT03377881. All study participants have given written informed consent to publish these case details. All data were analysed anonymously.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data used for simulation from the Stockholm PSA and Biopsy Register (SPBR) are potentially identifiable and data access to those data has been restricted by the Stockholm Ethical Review Board. The authors do not own these data and had no special privileges in accessing the data. Anyone wishing to access the individual level data would need to apply for permission through an Ethical Review Board and from the primary data owners, including the Swedish National Board of Health and Welfare and Karolinska Institutet. https://github.com/mclements/prostata